Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
4,094.00
-2,378.00
-58.09%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
4,094.00
-2,378.00
-58.09%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
11.00
-343.00
-3,118.18%
Raw Materials Consumed
1,295.00
581.00
714.00
122.89%
Power & Fuel Cost
5.00
93.00
-88.00
-94.62%
Employee Cost
257.00
515.00
-258.00
-50.10%
Operating Expenses
18.00
210.00
-192.00
-91.43%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
105.00
-12.00
-11.43%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
86.00
-73.00
-84.88%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
1,950.00
-488.00
-25.03%
Operating Profit (PBDIT) excl Other Income
253.00
2,144.00
-1,891.00
-88.20%
Other Income
40.00
321.00
-281.00
-87.54%
Operating Profit (PBDIT)
294.00
2,465.00
-2,171.00
-88.07%
Interest
1.00
19.00
-18.00
-94.74%
Profit before Depriciation and Tax
293.00
2,446.00
-2,153.00
-88.02%
Depreciation
39.00
220.00
-181.00
-82.27%
Profit Before Taxation & Exceptional Items
253.00
2,226.00
-1,973.00
-88.63%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
2,226.00
-2,070.00
-92.99%
Provision for Tax
40.00
375.00
-335.00
-89.33%
Profit After Tax
115.00
1,850.00
-1,735.00
-93.78%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
4,226.00
-3,648.00
-86.32%
Profit Available for appropriations
693.00
6,076.00
-5,383.00
-88.59%
Appropriations
693.00
6,076.00
-5,383.00
-88.59%
Equity Dividend (%)
1600%
300%
1,300.00
Earnings Per Share
46.3
103.31
-57.01
-55.18%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024






